Novartis in the NEWS
Basel, March 20, 2026 – Novartis (NVS) today announced that it has entered into an agreement with Synnovation Therapeutics, LLC to acquire SNV4818, a pan-mutant‑selective PI3Kα inhibitor, exploring a next-generation approach for the treatment of patients with HR+/HER2- breast cancer and potentially other solid tumor indications.

SNV4818

SNV4818 is an oral drug currently . . .